Hyrimoz (Adalimumab-adaz) for Psoriasis

Overview
Hyrimoz is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with moderate to severe plaque psoriasis and active psoriatic arthritis. Hyrimoz is also approved to treat rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, adult Crohn’s disease, and ulcerative colitis. Hyrimoz is also referred to by its drug name, adalimumab-adaz.

Hyrimoz is a member of a class of drugs called tumor necrosis factor (TNF) blockers. Hyrimoz is believed to work by blocking the activity of TNF, a substance that can cause inflammation and immune system diseases. Hyrimoz is biologically similar to the FDA-approved drug Humira (adalimumab).

How do I take it?
Prescribing information states that Hyrimoz is taken every other week.

Hyrimoz comes in the form of a subcutaneous injection.

Side effects
The FDA-approved label for Hyrimoz lists common side effects including upper respiratory infections, headache, rash, and injection site reactions like redness, swelling, itching, and bruising.

Rare but serious side effects listed for Hyrimoz include serious infections, severe allergic reactions, cancer, low blood counts, demyelinating diseases (such as multiple sclerosis or Guillain-Barre syndrome), heart failure, and lupus-like syndrome.

For more details about this treatment, visit:

Hyrimoz — Sandoz
https://www.sandoz.ca/en/products/patients/bios...